8 Amendments of Carlo CALENDA related to 2021/2013(INI)
Amendment 118 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2 a. Highlights the importance of a research-based pharmaceutical industry as an essential contributor to safeguarding quality manufacturing and supply of affordable medicines to reach all patients in need, strengthening the Union’s innovation, resilience, accessibility and responsiveness and helping address future challenges;
Amendment 160 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Considers that investment in research has not been sufficient to meet the therapeutic needs of patients with rare diseases, paediatric cancers and neurodegenerative diseases or to deal with antimicrobial resistance (AMR); calls on the Commission to strengthen industrial policy in the pharmaceutical sector and stimulate investment in non-patented paediatric medicines;
Amendment 165 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Supports the Commission in its objective of designing a new EU industrial strategy in an effort to achieve a more competitive and resilient industry when contending with global shocks;
Amendment 225 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Emphasises the need to support continuing innovation in the area of non- patented medicines as well, with a view to offering patients appropriate treatment; calls on the Commission to ensure that such medicines remain affordable for both health systems and patients;
Amendment 557 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Urges the Commission, based on the experience with the authorisation of COVID-19 vaccines, to work with the EMA to consider extending the application of rolling reviews to other emergency medicines; further calls on the Commission to work with the EMA and the European regulatory network to develop the use of electronic product information for all medicines in the EU;
Amendment 602 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Points out that the underlying causes of medicine shortages should be tackled and assessed in the light of the lack of a European industrial policy and that the links between the supply chain and production challenges should be addressed as a matter of urgency with a view to guaranteeing the independence of European pharmaceutical production;
Amendment 625 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20a. Welcomes the establishment of structured dialogue on production and the supply chain with the actors in the pharmaceutical value chain and the public authorities with a view to identifying the weak points in the global supply chain for critical medicines, raw materials and active ingredients; in that connection, urges the Commission, the Member States and stakeholders to draw up a clear and ambitious political roadmap of economic, legislative and industrial measures designed to safeguard and modernise medicine production capacity and stimulate investment in security of supply and improved production;
Amendment 636 #
Motion for a resolution
Paragraph 20 b (new)
Paragraph 20 b (new)
20b. Urges the Commission, in the context of Directive 2014/24/EU on public procurement, to put forward guidelines for the Member States which are designed in particular to steer contracting authorities towards applying the award criterion of the most economically advantageous tender rather than that of the lowest price; takes the view that investment in the production of active ingredients and medicinal products in the European Union, security of supply, the reinvestment of profits in research and development and the application of social, environmental, ethical and quality standards should be taken into account in assessing bids;